• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

JB Chemicals gets ANDA approval from US FDA for Loratadine Tablets

expresspharmaJanuary 12, 2021

Tag: JB Chemicals , ANDA , FDA , Loratadine Tablets , Allergic rhinitis

The US FDA has approved JB Chemicals & Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.

They are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use.

This product is generic version of Clartin tablet in the same strength of Bayer Healthcare. The company expects to commercialise this product in Q1 of FY 2021-22.

Previous:Japan Health Ministry finds new coronavirus variant

Next:Irisys Receives NIH Contract for the Formulation of Drinabant

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

JB Chemicals gets ANDA approval from US FDA for Loratadine Tablets | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

High-standard Influenza Vaccine (Split virion), inactivated

High-standard Influenza Vaccine (Split virion), inactivated
Depth Filter Sheets Standard Series

Depth Filter Sheets Standard Series
Deoxycyline (FDA)

Deoxycyline (FDA)
Bumetanide (FDA)

Bumetanide (FDA)
DLSB-5-30 New Standard Working Cycle Chiller For Lab Use

DLSB-5-30 New Standard Working Cycle Chiller For Lab Use
C 6000 global standards Package 2/12

C 6000 global standards Package 2/12
pharmaceutical Carbetocin Acetate(GMP standard product) Peptide

pharmaceutical Carbetocin Acetate(GMP standard product) Peptide
Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals
Marya GMP Standard Electronic Pharmaceutical Cleanroom Cargo Air Shower with High Efficiency System

Marya GMP Standard Electronic Pharmaceutical Cleanroom Cargo Air Shower with High Efficiency System
GMP Standard Factory Supply Amygdalin 98%

GMP Standard Factory Supply Amygdalin 98%

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service